Cargando…
Contrasting PTH Response of Denosumab Use in Dialysis Patients: A Report of 2 Cases
A common complication of end-stage renal disease (ESRD) is mineral and bone disorder. Yet, many anti-osteoporotic drugs are contraindicated in ESRD patients. Denosumab, a monoclonal antibody, does not require renal dose adjustment. However, its use is uncertain due to a lack of safety and efficacy o...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355881/ https://www.ncbi.nlm.nih.gov/pubmed/32244607 http://dx.doi.org/10.3390/pharmacy8020059 |